Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 9/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL1683285 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13743095 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14627881 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL15091182 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL19993736 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL23936980 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL183608 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL12567266 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL464782 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14621551 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184058-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AORTIC ANEURYSM | NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2022-06-16 | — | — | US | disclosed |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | RESVERLOGIX CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | HMGCR 82/4885SLCO1B1 656/4885SLC22A8 650/4885 |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | TOE1, ATF1, ELF3 | HMGCR 3873/4885SLCO1B1 4646/4885SLC22A8 3343/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | HMGCR 76/4885SLCO1B1 608/4885SLC22A8 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.